68Ga-DOTATATE PET imaging in clinically non-functioning pituitary macroadenomas
Abstract Purpose Clinically non-functioning pituitary macroadenomas (NFMA) have been reported to express somatostatin receptors (SSTR), but results are inconsistent across different studies. This may be related to limited sensitivity and specificity of techniques used to date, i.e. immunohistochemis...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SpringerOpen
2020-02-01
|
| Series: | European Journal of Hybrid Imaging |
| Subjects: | |
| Online Access: | http://link.springer.com/article/10.1186/s41824-020-0073-3 |
| _version_ | 1818955721913401344 |
|---|---|
| author | Tessel M. Boertien Jan Booij Charles B. L. M. Majoie Madeleine L. Drent Alberto M. Pereira Nienke R. Biermasz Suat Simsek Ronald Groote Veldman Marcel P. M. Stokkel Peter H. Bisschop Eric Fliers |
| author_facet | Tessel M. Boertien Jan Booij Charles B. L. M. Majoie Madeleine L. Drent Alberto M. Pereira Nienke R. Biermasz Suat Simsek Ronald Groote Veldman Marcel P. M. Stokkel Peter H. Bisschop Eric Fliers |
| author_sort | Tessel M. Boertien |
| collection | DOAJ |
| description | Abstract Purpose Clinically non-functioning pituitary macroadenomas (NFMA) have been reported to express somatostatin receptors (SSTR), but results are inconsistent across different studies. This may be related to limited sensitivity and specificity of techniques used to date, i.e. immunohistochemistry in surgical specimens and 111In-DTPA-octreotide scintigraphy in vivo. The aim of this study was to assess SSTR expression in NFMA in vivo using 68Ga-DOTATATE PET, which offers superior sensitivity and spatial resolution as compared with planar scintigraphy or SPECT. Methods Thirty-seven patients diagnosed with NFMA underwent 68Ga-DOTATATE PET/CT of the head in the framework of a randomised controlled trial assessing the effect of the somatostatin analogue lanreotide on NFMA size. Individual co-registered T1-weighted pituitary MRIs were used to assess 68Ga-DOTATATE uptake (SUVmean) in the adenoma. An SUVmean of > 2 was considered positive. Results 68Ga-DOTATATE uptake was positive in 34/37 patients (92%), with SUVmean of positive adenomas ranging from 2.1 to 12.4 (mean ± SD 5.8 ± 2.6). Conclusions This is the first report of 68Ga-DOTATATE PET performed in NFMA patients, demonstrating in vivo SSTR expression in the vast majority of cases. The high positivity rate when compared with results obtained with 111In-DTPA-octreotide scintigraphy probably reflects the superior sensitivity of PET imaging. Trial registration Netherlands Trial Register, NL5136, registered on 18 August 2015; EudraCT, 2015-001234-22, registered on 10 March 2015, https://eudract.ema.europa.eu/ |
| first_indexed | 2024-12-20T10:42:34Z |
| format | Article |
| id | doaj.art-dfc40eab25604fceb97c60979279d724 |
| institution | Directory Open Access Journal |
| issn | 2510-3636 |
| language | English |
| last_indexed | 2024-12-20T10:42:34Z |
| publishDate | 2020-02-01 |
| publisher | SpringerOpen |
| record_format | Article |
| series | European Journal of Hybrid Imaging |
| spelling | doaj.art-dfc40eab25604fceb97c60979279d7242022-12-21T19:43:31ZengSpringerOpenEuropean Journal of Hybrid Imaging2510-36362020-02-01411710.1186/s41824-020-0073-368Ga-DOTATATE PET imaging in clinically non-functioning pituitary macroadenomasTessel M. Boertien0Jan Booij1Charles B. L. M. Majoie2Madeleine L. Drent3Alberto M. Pereira4Nienke R. Biermasz5Suat Simsek6Ronald Groote Veldman7Marcel P. M. Stokkel8Peter H. Bisschop9Eric Fliers10Department of Endocrinology and Metabolism, Amsterdam UMC, University of AmsterdamDepartment of Radiology and Nuclear Medicine, Amsterdam UMC, University of AmsterdamDepartment of Radiology and Nuclear Medicine, Amsterdam UMC, University of AmsterdamDepartment of Internal Medicine, Section of Endocrinology, Amsterdam UMC, VU UniversityDepartment of Medicine, Division of Endocrinology, and Center for Endocrine Tumors Leiden (CETL), Leiden University Medical CenterDepartment of Medicine, Division of Endocrinology, and Center for Endocrine Tumors Leiden (CETL), Leiden University Medical CenterDepartment of Internal Medicine, Section of Endocrinology, Amsterdam UMC, VU UniversityDepartment of Internal Medicine, Medical Spectrum TwenteDepartment of Nuclear Medicine, Netherlands Cancer InstituteDepartment of Endocrinology and Metabolism, Amsterdam UMC, University of AmsterdamDepartment of Endocrinology and Metabolism, Amsterdam UMC, University of AmsterdamAbstract Purpose Clinically non-functioning pituitary macroadenomas (NFMA) have been reported to express somatostatin receptors (SSTR), but results are inconsistent across different studies. This may be related to limited sensitivity and specificity of techniques used to date, i.e. immunohistochemistry in surgical specimens and 111In-DTPA-octreotide scintigraphy in vivo. The aim of this study was to assess SSTR expression in NFMA in vivo using 68Ga-DOTATATE PET, which offers superior sensitivity and spatial resolution as compared with planar scintigraphy or SPECT. Methods Thirty-seven patients diagnosed with NFMA underwent 68Ga-DOTATATE PET/CT of the head in the framework of a randomised controlled trial assessing the effect of the somatostatin analogue lanreotide on NFMA size. Individual co-registered T1-weighted pituitary MRIs were used to assess 68Ga-DOTATATE uptake (SUVmean) in the adenoma. An SUVmean of > 2 was considered positive. Results 68Ga-DOTATATE uptake was positive in 34/37 patients (92%), with SUVmean of positive adenomas ranging from 2.1 to 12.4 (mean ± SD 5.8 ± 2.6). Conclusions This is the first report of 68Ga-DOTATATE PET performed in NFMA patients, demonstrating in vivo SSTR expression in the vast majority of cases. The high positivity rate when compared with results obtained with 111In-DTPA-octreotide scintigraphy probably reflects the superior sensitivity of PET imaging. Trial registration Netherlands Trial Register, NL5136, registered on 18 August 2015; EudraCT, 2015-001234-22, registered on 10 March 2015, https://eudract.ema.europa.eu/http://link.springer.com/article/10.1186/s41824-020-0073-3Non-functioning pituitary adenomaSomatostatin receptors68Ga-DOTATATEPET/CTMRI co-registration |
| spellingShingle | Tessel M. Boertien Jan Booij Charles B. L. M. Majoie Madeleine L. Drent Alberto M. Pereira Nienke R. Biermasz Suat Simsek Ronald Groote Veldman Marcel P. M. Stokkel Peter H. Bisschop Eric Fliers 68Ga-DOTATATE PET imaging in clinically non-functioning pituitary macroadenomas European Journal of Hybrid Imaging Non-functioning pituitary adenoma Somatostatin receptors 68Ga-DOTATATE PET/CT MRI co-registration |
| title | 68Ga-DOTATATE PET imaging in clinically non-functioning pituitary macroadenomas |
| title_full | 68Ga-DOTATATE PET imaging in clinically non-functioning pituitary macroadenomas |
| title_fullStr | 68Ga-DOTATATE PET imaging in clinically non-functioning pituitary macroadenomas |
| title_full_unstemmed | 68Ga-DOTATATE PET imaging in clinically non-functioning pituitary macroadenomas |
| title_short | 68Ga-DOTATATE PET imaging in clinically non-functioning pituitary macroadenomas |
| title_sort | 68ga dotatate pet imaging in clinically non functioning pituitary macroadenomas |
| topic | Non-functioning pituitary adenoma Somatostatin receptors 68Ga-DOTATATE PET/CT MRI co-registration |
| url | http://link.springer.com/article/10.1186/s41824-020-0073-3 |
| work_keys_str_mv | AT tesselmboertien 68gadotatatepetimaginginclinicallynonfunctioningpituitarymacroadenomas AT janbooij 68gadotatatepetimaginginclinicallynonfunctioningpituitarymacroadenomas AT charlesblmmajoie 68gadotatatepetimaginginclinicallynonfunctioningpituitarymacroadenomas AT madeleineldrent 68gadotatatepetimaginginclinicallynonfunctioningpituitarymacroadenomas AT albertompereira 68gadotatatepetimaginginclinicallynonfunctioningpituitarymacroadenomas AT nienkerbiermasz 68gadotatatepetimaginginclinicallynonfunctioningpituitarymacroadenomas AT suatsimsek 68gadotatatepetimaginginclinicallynonfunctioningpituitarymacroadenomas AT ronaldgrooteveldman 68gadotatatepetimaginginclinicallynonfunctioningpituitarymacroadenomas AT marcelpmstokkel 68gadotatatepetimaginginclinicallynonfunctioningpituitarymacroadenomas AT peterhbisschop 68gadotatatepetimaginginclinicallynonfunctioningpituitarymacroadenomas AT ericfliers 68gadotatatepetimaginginclinicallynonfunctioningpituitarymacroadenomas |